• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Microbiome Job Board

Editor’s Choice

Editor's Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview

June 27, 2022 Luis Gosálbez

First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

April 15, 2022 Laurence Zitvogel

 

Editor's Choice

Did you miss Probiota Copenhagen 2022? Catch up now!

April 12, 2022 Nina Vinot

With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]

Editor's Choice

A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology

February 18, 2022 Kristina Campbell

Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to […]

Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

February 17, 2022 Jean de Gunzburg

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Editor's Choice

Ferring takes pre-emptive action in IP dispute with Finch

February 2, 2022 Kristina Campbell

In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]

Editor's Choice

Food for Health: A new direction for American Agriculture

December 14, 2021 Andrew Benson and Bruce German

Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases […]

Editor's Choice

CRISPRing the microbiome is just around the corner

December 10, 2021 Robert Sanders, UC Berkley

To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]

Biotech Showcase

Bringing the Transformative Power of Synthetic Biology to Medicine

December 6, 2021 Aoife Brennan

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Editor's Choice

Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome

December 2, 2021 Microbiome Times

Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]

Posts navigation

1 2 … 10 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
    June 27, 2022
  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
sign up

Sign up to the Microbiome Times newsletter